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ABSTRACT 
 
OBJECTIVE 
 
The objective of this selective EBM review is to determine whether or not “Is methylphenidate 
effective in reducing apathy among Alzheimer’s disease patients?” 
 
STUDY DESIGN 
 
Systematic review of two randomized controlled trials published in 2008 and 2013 and one open 
label study published in 2010. 
 
DATA SOURCES 
 
Two randomized controlled trials and one open label study were obtained using PubMed and 
Medline. 
 
OUTCOMES MEASURED 
 
The focus of this review is to determine the efficacy of methylphenidate in decreasing symptoms 
of apathy in Alzheimer’s disease patients. The efficacy of methylphenidate was assessed in all 
three studies by using the Apathy Evaluation Scale (AES). The significance of these outcomes 
was also determined by calculating the relative benefit increase, the absolute benefit increase and 
the numbers needed to treat. 
 
RESULTS 
 
All three studies demonstrated improvement of AES score when treated with methylphenidate. 
The study by Padala et al. demonstrated a 20.26-point improvement on the AES with 
methylphenidate treatment. The study by Herrmann et al. demonstrated a 2.31-point 
improvement on the AES in the experimental group and the study by Rosenburg et al. 
demonstrated a 1.9-point improvement on the AES in the experimental group.  
 
CONCLUSIONS 
 
The studies analyzed in this selective EBM review suggest that methylphenidate is effective at 
improving apathy in Alzheimer’s disease patients. The studies by Padala et al. and Herrmann et 
al. demonstrated statistically significant results of apathy improvement in Alzheimer’s patients 
with methylphenidate treatment. Further analysis is warranted to determine tolerability based on 
dosing.  
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INTRODUCTION 
Dementia is a degenerative and irreversible brain disease that affects aspects of brain 
function including but not limited to memory, language, motor function and problem solving. 
Alzheimer’s disease is the most common form of dementia. Alzheimer’s disease is typically an 
indolent condition in which cognitive function gradually deteriorates until a person needs support 
for basic activities of daily living. The disease is especially burdensome on those afflicted by it 
and their families. It is estimated that there are currently 5.7 million Americans among all age 
groups that have Alzheimer’s dementia.1 Alzheimer’s disease is so prevalent that it is ranked as 
the sixth leading cause of death in the United States and is believed to be the third leading cause 
of death among older age groups.2 The cost of Alzheimer’s and all other types of dementias in 
2018 is estimated to be $277 billion.1 One report estimated that in 2017 the comprehensive 
lifetime cost of care for someone with dementia was $341,840.1 The same report shows that 
people with some type of dementia have more hospital and nursing home stays than people who 
do not have dementia.1 It is difficult to approximate how many healthcare visits there are each 
year as a result of dementia but one report found that there are 538 hospital stays per 1,000 
Medicare beneficiaries with some type of dementia compared to only 266 hospital stays per 
1,000 Medicare beneficiaries without dementia.1  
There are still a surprising number of things that are not well understood about 
Alzheimer’s disease such as the etiology, speed of progression, prevention, management and 
treatment of the disease. Some of the anatomical changes in the brain seen in Alzheimer’s 
disease include the development and buildup of extracellular beta-amyloid plaques and 
intracellular neurofibrillary tangles. These changes ultimately lead to inflammation and atrophy 
of the brain. Some research suggests that the anatomical changes seen in Alzheimer’s disease 
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may take place up to twenty years before symptoms are manifested.1 The greatest risk factors for 
developing Alzheimer’s disease include old age, family history and certain forms of the APOE 
gene.1  
Alzheimer’s disease most likely develops due to changes that occur in the brain over time 
from a combination of genetic, environmental and lifestyle factors. Early symptoms of 
Alzheimer’s disease can include memory difficulties, apathy and depression. Later in the course 
of Alzheimer’s disease, symptoms can include problems with communication, confusion, 
disorientation, poor judgement and behavioral changes. Treatment options for Alzheimer’s 
disease are limited to medications that may help with relief of symptoms due to the disease. 
There are no treatment options that can reverse or cure Alzheimer’s disease. FDA approved 
medications to treat Alzheimer’s disease include cholinesterase inhibitors such as donepezil, 
rivastigmine, galantamine, and N-methyl D-aspartate (NMDA) antagonists such as memantine.2 
After careful analysis of risks vs. benefits, other treatments can include antidepressants for 
depression, sleep aids for insomnia or other sleeping disturbances, anxiolytics for agitation and 
antipsychotics for agitation and aggression.3  
One study investigating the prevalence of neuropsychiatric symptoms in Alzheimer’s 
disease found that the symptoms with the highest prevalence included depression and apathy.4 
Apathy in Alzheimer’s disease is defined as a decrease in enthusiasm and motivation and as well 
as a loss of interest in things that one previously found intriguing.5 Alzheimer’s disease patients 
experiencing apathy often have impaired activities of daily living which can lead to an increased 
dependence on caretakers, a higher risk of long-term care and increased health care costs.5,6 
Thus, improving symptoms of apathy in Alzheimer’s disease could help improve quality of life. 
The same study revealed that activity in the dopaminergic mesolimbic brain reward system is 
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significantly associated with motivation and using a dopamine uptake inhibitor like 
methylphenidate may help to reduce symptoms of apathy.6  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Is 
methylphenidate effective in reducing apathy among Alzheimer’s disease patients?” 
METHODS  
 The three studies selected for this review were found in the PubMed and Medline 
databases. Key words used while searching for relevant studies included “methylphenidate” and 
“Alzheimer”. Inclusion criteria for study selection consisted of studies that assessed apathy with 
the Apathy Evaluation Scale (AES), studies that were written in English during 2008 or later, 
studies that involved primary research and studies that were published in a peer reviewed 
journal. Exclusion criteria for study selection consisted of studies that used medications other 
than methylphenidate and studies that investigated treatment for symptoms other than apathy 
among Alzheimer patients. The articles selected for this review were chosen based on relevance 
to the clinical question and having patient-oriented outcomes (POEMs). The statistics reported in 
these studies include: Z scores, p-values and mean change from baseline. Similar statistics were 
used in all studies with p values determined to be significant if values were < 0.05.  
Two randomized controlled trials from 2008 and 2013 and one open label study from 
2010 were selected for this systematic review. The target population used to aid in selection of 
studies included male and female patients diagnosed with Alzheimer’s disease who were 
experiencing symptoms of apathy. Methylphenidate, the intervention being evaluated for this 
review, was used in all three studies selected. All three studies selected initiated patients on a 
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10mg daily dose of methylphenidate and then increased the dose to 20mg daily. Table 1 shows 
the characteristics and demographics of the selected studies for this review. 
Table 1: Demographics & characteristics of included studies 
 
Study Type # 
Pts 
Mean 
age 
(SD) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Herrmann, 
et al.6 
Double 
Blind 
RCT 
13 78 (8) Dx of possible 
or probable 
AD, > 55y/o, 
MMSE > 10, 
presence of 
apathy on 
Neuropsychiat
ric Inventory 
(NPI), stable 
on ChEI for 
three months 
Current use of 
any psychotropic 
medication other 
than a ChEI, A-
fib, uncontrolled 
HTN, seizure 
disorder  
2 Methylpheni
date (5mg 
BID for 3 
days, then 
10mg BID 
for the 
remaining 11 
days) 
Padala, et 
al.7 
Open 
label 
study 
23 70 
(10)  
Diagnosis of 
DAT 
(Dementia of 
the 
Alzheimer’s 
type), AES 
>40, MMSE 
>18, stable 
dose of ChEI 
for 2 months,  
History of hyper-
sensitivity to 
methylphenidate, 
uncontrolled 
HTN, MI in the 
last 6 months, use 
of MAOI’s, use 
of other stimulant 
or Clonidine, 
Tourette 
syndrome, Closed 
angle glaucoma  
0 Methylpheni
date (5mg 
BID for the 
first two 
weeks, then 
10mg BID 
for the 
remaining 10 
weeks) 
Rosenburg
, et al.5 
Double 
Blind 
RCT, 
cross- 
over 
trial 
60 76 (8) Dx of possible 
or probable 
AD, MMSE 
>10, clinically 
significant 
apathy for at 
least four 
weeks 
determined by 
NPI, Stable 
dose if on 
SSRI 
Dx of major 
depressive 
Episode, 
agitation, 
aggression, 
delusions, 
hallucinations, 
psychotropic 
medication use 
except Trazadone 
or SSRI 
6 Methylpheni
date (10mg 
QD for 3 
days, then 
increased to 
20mg QD for 
the 
remainder of 
the study) 
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OUTCOMES MEASURED 
Apathy among participants was measured in all three studies using the Apathy Evaluation 
Scale (AES), the most reliable scale to measure apathy in Alzheimer’s disease.5 The AES is an 
18-item scale that can be scored from one to four for each item. The AES evaluates apathy in 
behavioral, cognitive and emotional domains. Scores on the AES can range from 18 to 72, with 
lower scores indicating that the patient is experiencing less apathy. All three studies chosen for 
this review measured the mean change in apathy based on the AES before and after treatment 
with methylphenidate.  
In the study by Herrmann et al., AES scores were assessed at weeks zero, two, three and 
five.6 In Padala et al.’s open label study, AES was measured at weeks zero, four, eight and 
twelve.7 Adverse effects were documented at each visit and physicians were allowed to lower the 
dose if needed due to adverse effects.7 The primary outcome measured in the study by 
Rosenburg et al.5 was the change in apathy based on the AES from baseline to the end of the 
study. The length of the study by Rosenburg et al. was six weeks. The researchers in the study by 
Rosenburg et al. documented adverse effects using a symptom checklist for expected side effects 
of methylphenidate and also asked open ended questions for unanticipated side effects.5 The 
focus of this EBM review will be to analyze the change in AES score from baseline to the end of 
treatment in order to determine the efficacy of methylphenidate in reducing apathetic symptoms. 
RESULTS 
In Herrmann et al.’s crossover study, the primary outcome measured was the change in 
AES from baseline to the end of treatment (EOT).6 In this study, subjects were randomly 
assigned to the experimental or comparison group. Participants were started on 5mg of 
methylphenidate twice a day for three days which was then increased to 10mg twice a day for the 
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remaining eleven days.6 All subjects participated for two weeks in the experimental phase and 
two weeks in the control phase with a one-week washout period on placebo between each phase. 
The participants were given methylphenidate as treatment during the experimental phase and 
were given a visually matched placebo during the control phase. The mean age of participants 
was 78 years with a standard deviation of eight years. Inclusion/exclusion criteria for this study 
can be found in Table 1. Two withdrawals occurred during the experimental phase of this study 
due to adverse effects. The data from one of the withdrawals was not included in the control 
group analysis because the participant never started the control phase. The other withdrawal had 
already completed the control phase and the data from that participant was still utilized for data 
analysis. Documented adverse effects that resulted in withdrawal included delusions, physical 
aggression, insomnia and hallucinations. Other documented adverse effects that did not result in 
withdrawal included irregular heartbeat, nausea and dry mouth. 
In the study by Herrmann et al., the mean change in AES score (EOT – Baseline) among 
the experimental group was a decrease of 2.31 points with a standard deviation of 5.11.6 In 
comparison, there was an increase of 0.50 points with a standard deviation of 3.87 among the 
control group. A decrease of 2.31 points is a relatively small decrease on the AES however, this 
small magnitude of change still represents an improvement of apathetic symptoms. The efficacy 
of the intervention was assessed using the Wilcoxon Z test which calculated a Z score of -2.0 
with a p-value of 0.045. With statistical significance defined as a p-value < .05, these results 
were statistically significant. These statistics are summarized in Table 2.  
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Table 2: Mean change in AES scores from end of treatment to baseline 
Study Mean change in AES, 
methylphenidate group 
Mean change in 
AES, placebo group 
P-value 95% Confidence 
interval 
Herrmann et 
al.6 
-2.31 ± 5.11 0.50 ± 3.87 0.045 Not calculated 
Padala et al.7 -20.26 Not calculated  < 0.0001 Not calculated  
Rosenburg et 
al.5 
-1.9 0.6 0.23 -6.5 to 1.6  
 
Herrmann et al. also reported that 54% of participants showed a decline in AES score 
with methylphenidate treatment, while only 8% showed a decline in AES score when given 
placebo.6 From this data, the relative benefit increase (RBI) was calculated to be 5.75, the 
absolute benefit increase (ABI) was calculated to be 0.46 and the numbers needed to treat (NNT) 
was calculated to be 3. This means that for every 3 patients treated with methylphenidate one 
more patient will have a decrease in AES score than if treated with placebo. A decrease on the 
AES corresponds with a reduction in the severity or frequency of apathetic symptoms. The 
summary for these statistics can be found in Table 3. 
Table 3: Efficacy and statistical significance of methylphenidate in the treatment of apathy 
in Alzheimer’s disease 
 
Study Control 
Event Rate 
Experimental 
Event Rate 
Relative Benefit 
Increase 
Absolute 
Benefit 
Increase  
Numbers 
Needed to 
Treat   
Herrmann, 
et al.6 
0.08 0.54 5.75 0.46 3 
Rosenburg, 
et al.5 
0.10 0.18 0.8 0.08 13 
 
In the open label study by Padala et al., all participants were initiated on methylphenidate 
5mg twice daily for two weeks which was then increased to 10mg twice daily for the remaining 
ten weeks.7 The mean age of participants was 70 years with a standard deviation of 10 years. 
Mean AES scores decreased throughout this study with methylphenidate treatment. The mean 
Rinaldi, Methylphenidate for Dementia 
 
8 
decrease in AES score from baseline to the end of the study was 20.26 with a p-value of < 
0.0001. This result demonstrates a statistically significant decrease in apathy after treatment with 
methylphenidate. A reduction of 20.26 on the AES is a substantial decrease and corresponds with 
significant improvement of apathetic symptoms. The summary for these results can be found in 
Table 2. None of the participants withdrew from this study due to adverse effects. Documented 
adverse effects that occurred during this study included decreased appetite, increased blood 
pressure, cough, dizziness, decreased sleep, irritability, restless legs, mouth sores and increased 
arthritic knuckle pain.  
The primary assessment in the study by Rosenburg et al. was comparing AES scores 
from the end of treatment to baseline.5 Of the sixty subjects selected for this study, twenty-nine 
were randomly assigned to the experimental group and thirty-one were randomly assigned to the 
control group. Participants in the experimental group were started on 10mg of methylphenidate 
daily for three days which was then increased to 20mg daily for the remainder of the study. The 
mean change in AES score from the end of treatment to baseline among the experimental group 
was a decrease of 1.9 points and an increase of 0.6 points in the control group. The estimated 
treatment effect (methylphenidate – placebo) was calculated to be -2.5 with a p-value of 0.23 and 
a 95% confidence interval of (-6.5 to 1.6). These results indicate that the AES score change from 
end of treatment to baseline are not statistically significant. The decrease in AES score with 
methylphenidate treatment indicates improvement of apathy, but a decrease of 1.9 points on this 
72-point scale is a relatively small decrease. Rosenburg et al. also documented that 18% of 
participants in the experimental group had a greater than eight-point improvement on AES score 
after treatment compared to only 10% in the control group. From this data, a NNT value of 13 
was calculated. This means that for every thirteen Alzheimer’s disease patients experiencing 
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apathy treated with methylphenidate one more patient will have a greater than eight-point 
improvement on AES score than if treated with placebo. These results can be found in Table 3. 
In the study by Rosenburg et al., compliance to taking the medication or placebo was 
calculated by checking the remaining number of pills per bottle at the end of the study.5 There 
was a calculated 88.3% compliance in the experimental group and 86.8% compliance in the 
control group.5 The studies by Herrmann et al.6 and Padala et al.7 did not include information 
about compliance. Rosenburg et al. defined serious adverse effects as adverse effects that led to 
hospitalization or emergency room visits.5 There were two incidents of serious adverse effects 
which included a drop in hemoglobin in one participant from the control group and abdominal 
pain in one participant from the experimental group. Adverse effects including hypertension, 
nervousness, nausea and anxiety led to four withdrawals in the experimental group. Adverse 
effects including insomnia and a drop in hemoglobin led to two withdrawals in the control group.  
DISCUSSION 
 The purpose of this review is to investigate the efficacy of methylphenidate in reducing 
symptoms of apathy in patients with Alzheimer’s disease. All three studies analyzed in this 
review demonstrated improvement of apathy on the AES in Alzheimer’s disease patients when 
treated with methylphenidate, but only Padala et al. and Herrmann et al. had statistically 
significant results.5-7 The study by Herrmann et al. was limited by having a particularly small 
sample size and a short treatment duration.6 Herrmann et al. also stated that the small sample size 
and study length may have impeded the ability to detect a more prominent response to 
methylphenidate.6 Herrmann et al. suggested that conditions such as ADHD and age-related 
declines in dopamine function may also be reasons for minimal responses to dopaminergic 
agents.6 The dose of methylphenidate chosen for this study was determined to be appropriate 
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based on other studies that investigated the use of methylphenidate in elderly Alzheimer’s 
disease patients experiencing apathy.6 Further investigation should be done to compare the 
tolerability and efficacy of different dosing formulations of methylphenidate.  
 Padala et al. pointed out that there were several limitations in the study they conducted.7 
One major limitation is due to the nature of this study. Padala et al. performed an open label 
study, meaning that the participants and the physicians were both cognizant of the treatment 
being administered. Some of the other limitations in this study are that there was no blinding for 
participants or providers and that there was no control group for comparison. Another 
shortcoming for this study is that the participants recruited were mostly males and only veterans, 
which limits the generalizability of the results.7   
 Rosenburg et al. identifies the following as some of the limitations of their study: 
recruiting a small sample size, having a limited set of measured outcomes, performing the study 
over a short duration and assessing only one dose of methylphenidate.5  
 Methylphenidate is a stimulant medication that blocks the reuptake of noradrenaline and 
dopamine and is currently indicated for the treatment of ADHD and narcolepsy.8 
Methylphenidate is a controlled substance but is still used commonly when indicated. Some of 
the most common adverse drug reactions from methylphenidate include decreased appetite, 
motor tics, sleep disturbances, changes in mood and increases in blood pressure and heart rate.8 
Some research suggests that methylphenidate may improve depression secondary to surgery or 
medical illness and in select groups such as stroke patients, cancer patients and HIV infected 
patients.8 Insurance coverage and access to the medication were not issues in the studies chosen 
for this review. 
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CONCLUSIONS 
The results from the studies selected for this review demonstrate that methylphenidate 
may be an effective treatment option for apathy in Alzheimer’s disease. Statistically significant 
reductions in apathy on the AES were observed in two of the studies reviewed. Improvement in 
apathy may lead to less dependence on caregivers and improved quality of life. In addition to 
having longer trial durations and more participants, future research should be done to compare 
different dosage formulations of methylphenidate in order to determine an optimal therapeutic 
dose in terms of tolerability and efficacy. While methylphenidate cannot reverse or cure 
Alzheimer’s disease, many trials are currently being done to discover new interventions that may 
be curative. 
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